We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.
Oxford spinout EvOx Therapeutics will harness the body's own precision communications system to deliver drugs to specific parts of the body, with the aim of treating conditions which are currently untreatable – including those affecting the brain, as well as autoimmune diseases and cancers.
